Gene expression profiling of early primary breast cancer to identify prognostic markers and associated pathways
Retrospective series of primary breast cancer patients who received surgery between 1989 and 1992. Patients received adjuvant chemotherapy and/or adjuvant hormone therapy, or no adjuvant treatment. Tamoxifen was used as endocrine therapy for 5 years in ER+ BC patients. Patients who were <50 years of age, with lymph node positive tumors, or ER– and/or >3 cm in diameter, received adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) for six cycles, in a thrice weekly intravenous regime...
Provenance — who produced it, who reused it
Linked to 28 papers in the literature. Roles are inferred factual signals (who deposited the data vs who reused it), with counts — never a judgement about any author.
- Prognostic Significance of Progesterone Receptor–Positive Tumor... 2012 · 589 cites
- Changes of N6-methyladenosine modulators promote breast cancer p... 2019 · 168 cites
- Prognostic microRNA/mRNA signature from the integrated analysis... 2013 · 153 cites
- Downregulation of long noncoding RNA MALAT1 induces epithelial-t... 2015 · 151 cites
- BreastMark: An Integrated Approach to Mining Publicly Available... 2013 · 143 cites
- The miR-106b-25 cluster mediates breast tumor initiation through... 2018 · 91 cites
- E2F7 overexpression leads to tamoxifen resistance in breast canc... 2015 · 78 cites
- MVDA: a multi-view genomic data integration methodology 2015 · 74 cites
20 further papers cite this accession but reuse could not be confirmed.
Deep data QC
metadata only · no data-level QC for this typeStandardized, field-standard QC computed by touching the data — every metric states how it was obtained
measured = computed from the data · extrapolated/reported = derived or from the repository · dq-1.0 · provisional — verify independently